Search hospitals > West Virginia > Charleston
West Virginia University Charleston Division
Claim this profileCharleston, West Virginia 25304
Global Leader in Cancer
Global Leader in Leukemia
Conducts research for Tumors
Conducts research for Adenocarcinoma
Conducts research for Breast Cancer
172 reported clinical trials
5 medical researchers
Summary
West Virginia University Charleston Division is a medical facility located in Charleston, West Virginia. This center is recognized for care of Cancer, Leukemia, Tumors, Adenocarcinoma, Breast Cancer and other specialties. West Virginia University Charleston Division is involved with conducting 172 clinical trials across 379 conditions. There are 5 research doctors associated with this hospital, such as Steven J. Jubelirer, Ahmed A. Khalid, Ashley E. Meyer, and Mohamad H. Badawi.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Leukemia
Global LeaderCD5 positive
Stage II
Stage IV
Top PIs
Steven J. JubelirerWest Virginia University Charleston Division4 years of reported clinical research
Expert in Cancer
Studies Lung Cancer
30 reported clinical trials
78 drugs studied
Ahmed A. KhalidWest Virginia University Charleston Division1 year of reported clinical research
Expert in Cancer
Studies Non-Small Cell Lung Cancer
32 reported clinical trials
79 drugs studied
Ashley E. MeyerWest Virginia University Healthcare4 years of reported clinical research
Studies Leukemia
Studies Tumors
23 reported clinical trials
62 drugs studied
Mohamad H. BadawiWest Virginia University Charleston Division4 years of reported clinical research
Studies Cancer
Studies Tumors
17 reported clinical trials
54 drugs studied
Clinical Trials running at West Virginia University Charleston Division
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Squamous Cell Carcinoma
Prostate Cancer
Diffuse Large B-Cell Lymphoma
Multiple Myeloma
Ovarian Cancer
Ovarian Tumors
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at West Virginia University Charleston Division?
West Virginia University Charleston Division is a medical facility located in Charleston, West Virginia. This center is recognized for care of Cancer, Leukemia, Tumors, Adenocarcinoma, Breast Cancer and other specialties. West Virginia University Charleston Division is involved with conducting 172 clinical trials across 379 conditions. There are 5 research doctors associated with this hospital, such as Steven J. Jubelirer, Ahmed A. Khalid, Ashley E. Meyer, and Mohamad H. Badawi.